| Peptide and small molecule microarray for high throughput cell adhesion and functional assays JR Falsey, M Renil, S Park, S Li, KS Lam Bioconjugate chemistry 12 (3), 346-353, 2001 | 454 | 2001 |
| Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study A Younes, JM Connors, SI Park, M Fanale, MM O'Meara, NN Hunder, ... The Lancet Oncology 14 (13), 1348-1356, 2013 | 328 | 2013 |
| Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma CA Ramos, NS Grover, AW Beaven, PD Lulla, MF Wu, A Ivanova, T Wang, ... Journal of clinical oncology 38 (32), 3794, 2020 | 288 | 2020 |
| The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: report from COMPLETE, a prospective … SI Park, SM Horwitz, FM Foss, LC Pinter‐Brown, KR Carson, ST Rosen, ... Cancer 125 (9), 1507-1517, 2019 | 137 | 2019 |
| Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 … SM Smith, BN Pitcher, SH Jung, NL Bartlett, N Wagner-Johnston, SI Park, ... The Lancet Haematology 4 (4), e176-e182, 2017 | 89 | 2017 |
| Positron emission tomography–directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001 DO Persky, H Li, DM Stephens, SI Park, NL Bartlett, LJ Swinnen, PM Barr, ... Journal of Clinical Oncology 38 (26), 3003, 2020 | 88 | 2020 |
| The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma PM Bhende, SI Park, MS Lim, DP Dittmer, B Damania Leukemia 24 (10), 1781-1784, 2010 | 85 | 2010 |
| Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation … SI Park, J Shenoi, JM Pagel, DK Hamlin, DS Wilbur, N Orgun, AL Kenoyer, ... Blood, The Journal of the American Society of Hematology 116 (20), 4231-4239, 2010 | 80 | 2010 |
| Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy KM Au, SI Park, AZ Wang Science advances 6 (27), eaba8564, 2020 | 77 | 2020 |
| Diagnostic complexities of eosinophilia ND Montgomery, CH Dunphy, M Mooberry, A Laramore, MC Foster, ... Archives of Pathology & Laboratory Medicine 137 (2), 259-269, 2013 | 72 | 2013 |
| A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States KR Carson, SM Horwitz, LC Pinter‐Brown, ST Rosen, B Pro, ED Hsi, ... Cancer 123 (7), 1174-1183, 2017 | 71 | 2017 |
| A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma P Martin, NL Bartlett, KA Blum, S Park, K Maddocks, J Ruan, LA Ridling, ... Blood, The Journal of the American Society of Hematology 133 (11), 1201-1204, 2019 | 68 | 2019 |
| A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma T Phillips, PM Barr, SI Park, K Kolibaba, PF Caimi, S Chhabra, ... Investigational New Drugs 37, 297-306, 2019 | 64 | 2019 |
| A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations JM Pagel, N Orgun, DK Hamlin, DS Wilbur, TA Gooley, AK Gopal, SI Park, ... Blood, The Journal of the American Society of Hematology 113 (20), 4903-4913, 2009 | 60 | 2009 |
| A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B‐cell lymphoma SI Park, NS Grover, O Olajide, AS Asch, JG Wall, KL Richards, AL Sobol, ... British journal of haematology 175 (2), 281-289, 2016 | 58 | 2016 |
| Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103 CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park, KA Blum, SM Smith, ... Blood, The Journal of the American Society of Hematology 128 (21), 2510-2516, 2016 | 56 | 2016 |
| Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model JM Pagel, AL Kenoyer, T Bäck, DK Hamlin, DS Wilbur, DR Fisher, SI Park, ... Blood, The Journal of the American Society of Hematology 118 (3), 703-711, 2011 | 56 | 2011 |
| Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202 SM Smith, B Pitcher, SH Jung, NL Bartlett, N Wagner-Johnston, SI Park, ... Blood 124 (21), 3091, 2014 | 53 | 2014 |
| Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy IB Greenwell, AD Staton, MJ Lee, JM Switchenko, DF Saxe, JJ Maly, ... Cancer 124 (11), 2306-2315, 2018 | 51 | 2018 |
| Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma JM Connors, SM Ansell, M Fanale, SI Park, A Younes Blood, The Journal of the American Society of Hematology 130 (11), 1375-1377, 2017 | 51 | 2017 |
